Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer

AMSTERDAM, July 6, 2011 -

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in
the field of human gene therapy, today announced the appointment of
Dr. Carlos R. Camozzi as Chief Medical Officer. Dr. Camozzi brings
to AMT more than 25 years of pharmaceutical industry experience,
most recently within the orphan drug field. This includes
overseeing product approvals at the European Medicines Agency (EMA)
and U.S. Food and Drug Administration (FDA).

“We are very fortunate to have attracted Carlos to AMT. He has
joined the company at a pivotal point as we continue to pursue the
approval our lead gene therapy Glybera with the EMA,” stated Jörn
Aldag, CEO of AMT. “His expertise in product development and
related interaction with global regulatory bodies in the orphan
drug field will prove invaluable, not only with Glybera, but also
as we advance development of our gene therapy pipeline.”

Dr. Camozzi will join AMT on July 18 from Orphan Europe, where
he held the position of Medical Director for over 5 years. During
his tenure, he oversaw the approval of Carbaglu, a product for
hyperammonemia in NAGS deficiency and Organic Acidemias, with the
EMA and FDA, EMEA marketing authorisation renewals for two
products, three orphan drug designations and development of
pediatric investigation plans. He was also responsible for the
clinical development in the pediatric field of orphan drugs in
therapeutic areas of metabolic disorders, immunology, dermatology,
cardiology and CNS.

Prior to Orphan Europe, Dr. Camozzi was a strategic development
manager in the Molecular Pathology department of Basel University
Hospital, Basel, Switzerland. In this role, he interacted with both
pharmaceutical customers and regulatory authorities. From
2001-2005, he was managing director of MCP-medeor consulting
pharma, where he helped design preclinical and clinical development
programs for pharmaceutical and healthcare products. Dr. Camozzi
started his career in South America holding roles at
Lederle/American Cyanamid and F Hoffmann La-Roche.

Dr. Camozzi earned his MD and PhD from the School of Medicine,
National University of Buenos Aires (Argentina), and holds degrees
in Paediatrics, Neonatology, Clinical Pharmacology and
Neuropsychiatry.

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene
based therapies. The company’s lead product Glybera®, a gene
therapy for lipoprotein lipase deficiency (LPLD), is currently
under review by the European Medicines Agency (EMA). If approved,
Glybera will be the first gene therapy product to be marketed in
Europe. AMT also has a product pipeline of several gene therapy
products in development for hemophilia B, Duchenne muscular
dystrophy, acute intermittent porphyria, Parkinson’s disease and
SanfilippoB. Using adeno-associated viral (AAV) derived vectors as
the delivery vehicle of choice for therapeutic genes, the company
has been able to design and validate probably the world’s first
stable and scalable AAV manufacturing platform. This
proprietary platform can be applied to a large number of
rare (orphan) diseases caused by one faulty gene and allows
AMT to pursue its strategy of focusing on this sector of the
industry.  AMT was founded in 1998 and is based in Amsterdam.
Further information can be found at href="www.amtbiopharma.com">www.amtbiopharma.com.

Certain statements in this press release are
“forward-looking statements“ including
those that refer to management’s plans and expectations for future
operations, prospects and financial condition. Words such as
“strategy,““expects,““
plans,““anticipates,““believes,
““will,““continues,“
“estimates,““intends,““
projects,““goals,““targets
“ and other words of similar meaning are intended to
identify such forward-looking statements. Such statements are based
on the current expectations of the management of AMT only. Undue
reliance should not be placed on these statements because, by their
nature, they are subject to known and unknown risks and can be
affected by factors that are beyond the control of AMT. Actual
results could differ materially from current expectations due to a
number of factors and uncertainties affecting AMT‘s
business. AMT expressly disclaims any intent or obligation to
update any forward-looking statements herein except as required by
law. 

PRN NLD

For further enquiries:
Jörn Aldag
CEO
AMT
Tel : +31-20-566-7394
j.aldag at amtbiopharma.com

Mike Sinclair
Partner
Halsin Partners
Tel : +44-20-7318-2955
msinclair at halsin.com